With the acquisition, DaVita is said to broaden its efforts to fuel transplant innovation
MedSleuth acquired by DaVita. (Credit: Pete Linforth from Pixabay)
DaVita, a US-based kidney care provider, has acquired transplant software company MedSleuth for an undisclosed price, in a move to strengthen its presence along the kidney care journey.
MedSleuth is said to work with transplant centres in the US with an objective to create increased connectivity among transplant candidates, the centres, physicians and care teams to help enhance the experience and results for kidney and liver transplant patients.
Through the acquisition, DaVita is said to broaden its efforts to drive transplant innovation.
DaVita CEO Javier Rodriguez said: “Kidney transplantation is a life-changing option for most people with kidney failure, one that’s limited today by supply and complexity.
“MedSleuth has built a powerful platform that can help increase patients’ access to transplantation. We’re looking forward to supporting the team to accelerate innovation and help streamline the transplant process for transplant candidates, transplant centers, physicians and care teams.”
MedSleuth’s software is said to optimise the process of evaluating candidates and have them active on the waitlist. It is also claimed to help boost the rate of transplantation via living donation.
Furthermore, the transplant software is said to make it easier for the doctors and care teams of transplant candidates to help support them during the transplant journey.
MedSleuth’s flagship product is BREEZE. The software product platform is designed to help eliminate some of the obstacles for potential kidney and liver donors and recipients by collecting relevant clinical and demographic information remotely and sharing it with participating transplant centres.
The company’s paired exchange platform called MATCHGRID employs optimisation algorithms to detect chains for paired donation. The advanced enterprise software application is said to help clinicians at transplant centres quickly match living organ donors with recipients with willing, healthy but incompatible donors.
MedSleuth CEO and founder James Kalamas said: “We knew DaVita was the best long-term home for MedSleuth because we share a common vision to increase access to transplantation.
“Together, we’ll continue reimagining the transplant experience to help improve the lives of transplant patients.”